Navigation Links
CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
Date:9/29/2008

SARASOTA, Fla., Sept. 29 /PRNewswire-FirstCall/ -- CPC of America, Inc. (OTC Bulletin Board: CPCF.OB) today announced that it had retained FTI Capital Advisors, LLC, the investment banking subsidiary of FTI Consulting, Inc., to explore strategic alternatives for the Company.

As CPC of America's financial advisor, FTI Capital Advisors will report to the Board any expressions of interest from third parties seeking to pursue a possible licensing agreement or acquisition of the Company or its technology. CPC of America has authorized FTI Capital Advisors to contact parties and to report back so that the Board can evaluate any expressions of interest and determine whether a transaction would be in the best interests of shareholders. There can be no assurance that this process will result in any expressions of interest or a transaction, and the Company does not currently intend to publicly disclose further information regarding the status of its review until the process has been completed.

CPC of America also announced today that it has appointed FTI's Strategic Communications practice, FD, to provide public and investor relations counsel to the Company. One of the world's most sought-after business and financial communications consultancies, FD helps many of the world's leading organizations harness the power of communications to capitalize upon business opportunities. FD's Life Sciences group advises pharmaceutical and medical device entities ranging from global leaders to emerging, development-stage companies.

CPC of America's Chairman and CEO Rod A. Shipman notes, "CPC expects to benefit greatly from the counsel and support of FTI's consulting services in seeking to explore strategic alternatives and raise the visibility of our technology. We look forward to working with our advisors to examine and implement ways to maximize shareholder value."

About CPC

CPC of America acquires, develops and oversees the manufacturing of cardi
'/>"/>

SOURCE CPC of America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
2. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
3. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
6. Global Experts Explore Entire Spectrum of Aids Vaccine Development
7. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
8. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
9. Alfacell Hires Advisors to Advance Strategic Alternatives
10. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
11. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5